99%-Retatrutide-10mg/vial

Product Description

2mg 5mg 10mg Retatrutide 99% Peptides Vials CAS 1415456-99-3 Sema Tirz Retatrutide for Weight Loss Cagrilintide 

CagriSema injection is a combination therapy that includes the glucagon-like peptide-1 (GL-1) receptor agonist sema and the long-acting amylin analog cagrilintide . The therapy has weight loss benefits, but the effect on glycated hemoglobin (HbA1c) is unclear.


The 83rd American Diabetes Association Scientific Conference 2023 (ADA 2023) will be held in San Diego, USA on June 23, local time. A study was announced during the meeting, which evaluated the effectiveness and safety of CagriSema (sema combined with canaglitide) in patients with type 2 diabetes. Results showed that in patients with type 2 diabetes, treatment with CagriSema improved glycemic control and resulted in significant weight loss compared with sema or canaglitide monotherapy and was well tolerated with no new safety concerns. sexual signals.

This multi-center, double-blind, phase 2 trial included a total of 92 patients with a body mass index (BMI) ≥27 kg/m2 from 17 research centers in the United States from August 2 to October 18, 2021, who received metformin with or without metformin. Adult patients with type 2 diabetes (HbA1c 7.5%~10.0%) treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors were randomly assigned in a 1:1:1 ratio to receive a weekly subcutaneous injection of CagriSema ( n=31), sema (n=31), or canaglitide (n=30) (dose escalation to 2.4 mg over 16 weeks) for 32 weeks. Of these patients, 59 (64%) were male. The average age of patients was 58 years old. The primary endpoint of the study was the change in HbA1c from baseline. Secondary endpoints were body weight, fasting glucose, continuous glucose monitoring (CGM) parameters and safety.

Primary endpoints:

At week 32, the proportions of patients with HbA1c <7.0% and ≤6.5% were 89% and 75%, respectively, in the CagriSema group, 69% and 48%, respectively, in the sema group, and 69% and 48%, respectively, in the canaglitide group. 33% and 17%. Additionally, the mean change in HbA1c from baseline to week 32 was higher in the CagriSema group than in the canaglitide group (estimated treatment difference [ETD] -1.3 percentage points [95% CI -1.7 to -0.8]; P < 0.0001), but There was no difference compared with the sema group (ETD -0.4 percentage points [95% CI -0.8 to 0.0]; P=0.075).

The average changes in HbA1c in the 3 groups are:

CagriSema group: -2.2 percentage points;

Sema group: -1.8 percentage points;

Canaglitide group: -0.9 percentage points.

Secondary endpoints:

The average change in body weight from baseline to 32 weeks was higher in the CagriSema group than in the canaglitide group (P<0.0001) and the semag group (P<0.0001).


The average changes in body weight of the 3 groups are:

CagriSema group: -15.6%;

Sema group: -5.1%;

Canaglitide group: -8.1%.
The average change in fasting blood glucose from baseline to 32 weeks was higher in the CagriSema group than in the canaglitide group (P=0.0010), but there was no significant difference compared with the sema group (P=0.10).

The average changes in fasting blood glucose in the 3 groups are:

CagriSema group: -3.3 mmol/L;

Sema group: -2.5 mmol/L;

Canaglitide group: -1.7 mmol/L.

At baseline, the CagriSema group, sema group and canaglitide group spent 45.9%, 32.6% and 56.9% of their time within the range of 3.9~10.0 mmol/L respectively, and at week 32 they were 88.9% and 76.2 respectively. % and 71.7%.

 
Adverse events were reported by 21 (68%) subjects in the CagriSema group, 22 (71%) subjects in the sema group, and 24 (80%) subjects in the canaglitide group. The most common adverse events were mild or moderate gastrointestinal disorders. In addition, no grade 2 or 3 hypoglycemic events or fatal adverse events were reported in this study.

Overall, treatment with CagriSema resulted in clinically relevant improvements in glycemic control. The average change in HbA1c in the CagriSema group was greater than that in the canaglitide group, but there was no significant difference compared with the sema group. In addition, patients in the CagriSema group experienced significantly greater weight loss compared with the sema and canaglitide groups and were well tolerated. These data support a longer, larger Phase 3 study of CagriSema in this population.